Silver Book Fact

Treatment for hypertension using antihypertensive therapy has generated a benefit-to-cost ratio of at least 6:1.

Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux. The Value Of Antihypertensive Drugs: A perspective on medical innovation. Health Affairs. 2007; 26(1): 97-110

Reference

Title
The Value Of Antihypertensive Drugs: A perspective on medical innovation
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux
Volume & Issue
Volume 26, Issue 1
Pages
97-110

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • “Coronary heart disease spending has increased more than 40% over the past 15 years, and, as a whole, the health improvements have been well worth the costs. Over the entire…  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
  • Direct thrombin inhibitor reduced relative risk of venous thromboembolism
    An investigational direct thrombin inhibitor reduced relative risk of venous thromboembolism after total hip replacement surgery by 65.7%—compared to a currently available treatment.  
  • The development of antioxidants that reduce oxidative damage is underway. One antioxidant that has been found, uric acid, has an even greater protective effect when combined with tPA.  
  • Echocardiography and nuclear imaging are used for provocative “stress” testing of the heart. When combined with other forms of stress, both can identify the presence of coronary artery-obstructing lesions that…